Influence of CGS 21680, a selective adenosine A2A receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice

Brain Research

Volumn 1323, Issue , 2010, Pages 184-191

  Ferrante, Antonella ^a   Martire, Alberto ^a   Armida, Monica ^a   Chiodi, Valentina ^a   Pézzola, Antonella ^a   Potenza, Rosa Luisa ^a   Domenici, Maria Rosaria ^a   Popoli, Patrizia ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

A2A receptor; Brain slice; Cortex; Huntington's disease; NMDA receptor; Striatum

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; RECEPTOR SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENOTYPE; HUNTINGTON CHOREA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; BLOTTING, WESTERN; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; FEMALE; HUNTINGTON DISEASE; MALE; MICE; NEURONS; PHENETHYLAMINES; PROTEIN SUBUNITS; RECEPTORS, N-METHYL-D-ASPARTATE; STATISTICS, NONPARAMETRIC;

MUS;

EID: 77953129575     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.01.080     Document Type: Article

References (43)

1. Albin R.L., Young A.B., Penney J.B., Handelin B., Balfour R., Anderson K.D., Markel D.S., Tourtellotte W.W., and Reiner A. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N. Engl. J. Med. 322 (1990) 1293-1298
2. Ali N.J., and Levine M.S. Changes in expression of N-Methyl-D-Aspartate receptor subunits occur early in the R6/2 moue model of Huntington Disease. Dev. Neurosci. 28 (2006) 230-238
3. Anderson W.W., and Collingridge G.L. The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 15 (2001) 71-83
4. Azdad K., Gall D., Woods A.S., Ledent C., Ferré S., and Schiffmann S.N. Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 34 (2009) 972-986
5. Blum D., Galas M.C., Pintor A., Brouillet E., Ledent C., Muller C.E., Bantubungi K., Galluzzo M., Gall D., Cuvelier L., Rolland A.S., Popoli P., and Schiffmann S.N. A dual role of odenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. J. Neurosci. 23 (2003) 5361-5369
6. Cepeda C., Ariano M.A., Calvert C.R., Flores-Hernández J., Chandler S.H., Leavitt B.R., Hayden M.R., and Levine M.S. NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66 (2001) 525-539
7. Cha J.H., Frey A.S., Alsdorf S.A., Kerner J.A., Kosinski C.M., Mangiarini L., Penney Jr. J.B., Davies S.W., Bates G.P., and Young A.B. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354 (1999) 981-989
8. Chen N., Luo T., Wellington C., Metzler M., McCutcheon K., Hayden M.R., and Raymond L.A. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J. Neurochem. 72 (1999) 1890-1898
9. Chiang M.C., Chen H.M., Lai H.L., Chen H.W., Chou S.Y., Chen C.M., Tsai F.J., and Chern Y. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Hum. Mol. Genet. 15 (2009) 2929-2942
10. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., and Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 93 (2005) 310-320
11. Cull-Candy S., Brickley S., and Farrant M. NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11 (2001) 327-335
12. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13 (1990) 286-289
13. Dingledine R., Borges K., Bowie D., and Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51 (1999) 7-61
14. Domenici M.R., Pepponi R., Martire A., Tebano M.T., Potenza R.L., and Popoli P. Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)-mediated effects in the striatum. J. Neurochem. 90 (2004) 1276-1279
15. Domenici M.R., Scattoni M.L., Martire A., Lastoria G., Potenza R.L., Borioni A., Venerosi A., Calamandrei G., and Popoli P. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol. Dis. 28 (2007) 197-205
16. Ekonomou A., Poulou P.D., Matsokis N., and Angelatou F. Stimulation of adenosine A2A receptors elicits zif/268 and NMDA epsilon2 subunit mRNA expression in cortex and striatum of the "weaver" mutant mouse, a genetic model of nigrostriatal dopamine deficiency. Neuroscience 123 (2004) 1025-1036
17. Fan M.M.Y., and Raymond L.A. N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 81 (2007) 272-293
18. Ferrè S., Fredholm B.B., Morell M., Popoli P., and Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 20 (2007) 482-487
19. Flint A.C., Maisch U.S., Weishaupt J.H., Kriegstein A.R., and Monyer H. NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J. Neurosci. 17 (1997) 2469-2476
20. Gil J.M., and Rego A.C. Mechanisms of neurodegeneration in Huntington's disease. Eu. J. Neurosci. 27 (2008) 2803-2820
21. Glass M., Dragunow M., and Faull R.L. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97 (2000) 505-519
22. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., and Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J. Neurosci. 29 (2009) 3200-3205
23. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., and Chesselet M.F. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58 (1999) 515-532
24. Li S.-H., and Li X.-J. Huntingtin and its role in neuronal degeneration. Neuroscientist 10 (2004) 467-475
25. Luthi-Carter R., Strand A.D., Hanson S.A., Kooperberg C., Schilling G., La Spada A.R., Merry D.E., Young A.B., Ross C.A., Borchelt D.R., and Olson J.M. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Gen. 11 (2002) 1927-1937
26. Luthi-Carter R., Apostol B.L., Dunaha A.W., DeJohna M.M., Farrella L.A., Batesc G.P., Young A.B., Standaert D.G., Thompson L.M., and Cha J.H.J. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol. Dis. 14 (2003) 624-636
27. Martire A., Calamandrei G., Felici F., Scattoni M.L., Lastoria G., Domenici M.R., Tebano M.T., and Popoli P. Opposite effects of the A(2A) receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice. Neurosci. Lett. 417 (2007) 78-83
28. Martire A., Ferrante A., Potenza R.L., Armida M., Ferretti R., Pézzola A., Domenici M.R., and Popoli P. Remodeling of striatal NMDA receptors by chronic A2A receptor blockade in Huntington's disease mice. Neurobiol. Dis. 37 (2010) 99-105
29. Popoli P., Pintor A., Domenici M.R., Frank C., Tebano M.T., Pèzzola A., Scarchilli L., Quarta D., Reggio R., Malchiodi-Albedi F., Falchi M., and Massotti M. Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J. Neurosci. 22 (2002) 1967-1975
30. Popoli P., Blum D., Martire A., Ledent C., Ceruti S., and Abbracchio M.P. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog. Neurobiol. 81 (2007) 331-348
31. Popoli P., Blum D., Domenici M.R., Burnouf S., and Chern Y. A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr. Pharm. Des. 14 (2008) 1500-1512
32. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92 (2005) 433-441
33. Suopanki J., Götz C., Lutsch G., Schiller J., Harjes P., Herrmann A., and Wanker E.E. Interaction of huntingtin fragments with brain membranes-clues to early dysfunction in Huntington's disease. J. Neurochem. 96 (2006) 870-884
34. Tarditi A., Camurri A., Varani K., Borea P.A., Woodman B., Bates G., Cattaneo E., and Abbracchio M.P. Early and transient alteration of adenosine A(2A) receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23 (2006) 44-53
35. Tebano M.T., Domenici M.R., and Popoli P. SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slices. Eur. J. Pharmacol. 450 (2002) 253-257
36. Tebano M.T., Martire A., Rebola N., Pepponi R., Domenici M.R., Grò M.C., Schwarzschild M.A., Chen J.F., Cunha R.A., and Popoli P. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J. Neurochem. 95 (2005) 1188-1200
37. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
38. Varani K., Rigamonti D., Sipione S., Camurri A., Borea P.A., Cattabeni F., Abbracchio M.P., and Cattaneo E. Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant Huntingtin. FASEB J. 15 (2001) 1245-1247
39. Varani K., Abbracchio M.P., Cannella M., Cislaghi G., Giallonardo P., Mariotti C., Cattabriga E., Cattabeni F., Borea P.A., Squitieri F., and Cattaneo E. Aberrant A2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17 (2003) 2148-2150
40. Vicini S., Wang J.F., Li J.H., Zhu W.J., Wang Y.H., Luo J.H., Wolfe B.B., and Grayson D.R. Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J. Neurophysiol. 79 (1998) 555-566
41. Wirkner K., Gerevich Z., Krause T., Guenther A., Koeles L., Schneider D., Noerenberg W., and Illes P. Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacol. 46 (2004) 994-1007
42. Young A.B., Greenamyre J.T., Hollingsworth Z., Albin R., D'Amato C., Shoulson I., and Penney J.B. NMDA receptor losses in putamen from patients with Huntington's disease. Science 241 (1988) 981-983
43. Zeron M.M., Hansson O., Chen N., Wellington C.L., Leavitt B.R., Brundin P., Hayden M.R., and Raymond L.A. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33 (2002) 849-860